Voyager Therapeutics GAAP EPS of -$0.47, revenue of $2.6M
Source: SeekingAlpha
2026-05-07 17:05:58 ET
More on Voyager Therapeutics
- Voyager Therapeutics, Inc. (VYGR) Discusses Tracer AAV Capsid Platform for Enhanced CNS Gene Therapy Delivery Transcript
- Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
- Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
- Neurocrine Friedreich ataxia asset granted FDA orphan status
- Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge
Read the full article on Seeking Alpha
For further details see:
Voyager Therapeutics GAAP EPS of -$0.47, revenue of $2.6M
Voyager Therapeutics Inc.
NASDAQ: VYGR
VYGR Trading
-1.78% G/L:
$3.58 Last:
271,305 Volume:
$3.60 Open:
VYGR Latest News
June 01, 2026 08:00:00 am
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
VYGR Stock Data
$301,853,951
50,692,821
0.13%
37
N/A
Biotechnology & Life Sciences
Healthcare
US
Lexington
